Radiation Candidate a Keeper
Maxygen Has Maxi-Cash After Astellas Buyout of Perseid
By Tom Wall
Friday, March 18, 2011
Maxygen, Inc.'s shares and bank balance both grew rapidly on news that Tokyo-based partner Astellas Pharma Inc. exercised its option to buy out Maxygen's 83.3 percent equity interest in the companies' joint venture, Perseid Therapeutics LLC, for $76 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.